









Preliminary programme

Programme, Friday 17 January 2014

08.30 - 08.40	Welcome
08.40 - 09.00	Opening address
09.00 - 11.00	Prostate cancer I: Screening, diagnosis, staging and treatment
09.00 - 09.20	Prostate cancer screening: Why screening programme should not be adopted in > 65
09.20 - 09.30	Discussion
09.30 - 09.45	Diagnostic Strategies for early detection of PCa
09.45 - 11.00 09.45 - 10.00 10.00 - 10.15 10.15 - 10.30 10.30 - 10.45	Debate: Prostate biopsy and pathological evaluation: How to achieve maximum information Is it time to trash TRUS biopsy? The indication for prostate biopsy in 2014: MRI directed biopsy: Is it becoming a standard? How reliable is the pathological examination to make clinical decisions: The role of tissue biomarkers to predict prognosis
10.45 - 11.00	Discussion
11.00 - 11.15	Coffee break
11.15 - 12.15	Active treatment vs Active surveillance for Low risk PCa in young men
11.15 - 11.30	Robotic RP (video)
11.30 - 11.45	Focal therapy
11.45 - 12.00	Active survaillance
12.00 - 12.15	Discussion
12.15 - 13.45	Renal Cancer: Localised
12.15 - 12.30	Can we predict histology of renal tumors by imaging and macroscopic appearance? Clinical consequences
12.30 - 12.45	New pathological classification: Grading
12.45 - 13.45 12.45 - 13.00 13.00 - 13.15 13.15 - 13.30	Debate: The best treatment for renal masses > 3 cm in the elderly (>75) patients Active surveillance: Has it a role? Ablation therapy: Pro Surgery: Still the best?
13.30 - 13.45	Discussion





17-19 January 2014, Prague, Czech Republic





13.45 - 14.45	Luncii
14.45 - 15.15	Penile cancer
14.45 - 15.00	Pre-Malignant lesions: Incidence and Classifications
15.00 - 15.15	Mini-Invasive therapies for clinically localised penile tumours
15.15 - 16.15	Urothelial cancer I: Non muscle invasive
15.15 - 15.35	Circulating tumor cells in bladder cancer: A new marker?
15.35 - 16.15	Debate: Standard TUR and cytology vs TUR and new technologies Standard TUR: New technologies:
16.15 - 16.45	Coffee break
16.45 - 18.15	Urothelial cancer II: Non muscle invasive
16.45 - 17.30 16.45 - 17.00 17.00 - 17.15	Debate: Treatment of intermediate risk patients: Chemotherapy vs BCG Chemo is appropriate: BCG is the best:
17.15 - 17.30	Discussion
17.30 - 17.45	BCG in the elderly: Still a good choice?
17.45 - 18.00	Discussion
18.00 - 18.15	Best NMIBC papers in 2012 associate member





17-19 January 2014, Prague, Czech Republic

http://esou.uroweb.org



Programme, Saturday 18 January 2014

00.30 - 10.30	Flostate Calicel II. Localised
08.30 - 08.50	Treatment algorithm in high risk PCa
08.50 - 10.30	Debate: High risk clinically localised Pca
08.50 - 09.10	Radical prostatectomy: How I do it step by step (Video)
09.10 - 09.30	Radiotherapy is better: New technologies (Cyberknife, Protons)
09.30 - 09.50	Robotic Radical prostatectomy and Extended Lymphadenectomy for c T3 PCa: SURGICA TECHNIQUE AND outcomes (Video and lecture)
09.50 - 10.10	Laparoscopic RP for cT3: Same results but less expensive?
10.10 - 10.30	Discussion
10.30 - 11.30	Testicular cancer
10.30 - 10.45	Standard treatment and new messages in the management in Stage I disease
10.45 - 11.00	New messages in intermediate and poor risk disease
11.00 - 11.15	Surgical approaches in complex cases
11.15 - 11.30	Discussion
11.30 - 11.45	Coffee break
11.45 - 13.30	Urothelial cancer III: Muscle invasive and advanced disease
11.45 - 12.00	Radical cystectomy and orthotopic neobladder in women: Long term results and QoL
12.00 - 12.30	Debate: Prostate sparing Radical cystectomy
12.30 - 12.45	Discussion
12.45 - 13.40	Debate: Therapeutic Strategies in elderly (>75) and frail patients with muscle-invasive bladder cancer
12.45 - 12.55	Geriatric evaluation (definition of frail and clinical impact)
12.55 - 13.05	Surgery
13.05 - 13.15	Radio- chemotherapy
13.15 - 13.25	Local control and best supportive care
13.25 - 13.45	Discussion
14.00 - 16.00	STEPS programme (closed programme: participation by invitation only)





17-19 January 2014, Prague, Czech Republic

http://esou.uroweb.org



Programme, Sunday 19 January 2014

09.00 - 10.00	Disaster Management and prevention in uro-oncological surgery (open, robotic and lap)
09.00 - 09.20	Intra-OP
09.20 - 09.40	Late
09-40- 10.00	Case Discussion
10.00 - 11.15	Cytoreductive Surgery in metastatic disease
10.00- 10.15	Rationale
10.15-10.30	Kidney
10.30-10.45	Bladder
10.45-11.00	Prostate
11.00-11.15	Discussion
11.15 - 11.45	Coffee break
11.45- 12.35	Muscle invasive Bladder Cancer
11.45 - 12.05	Standardizing complications reporting after radical cystectomy
12.05- 12.25	Functional outcomes of orthotopic reservoirs following radical cystectomy. Searching the truth
12.25 -12.35	Discussion
12.35 - 13.40	Prostate Cancer III: Advanced and Metastatic
12.35- 12.50	Intermittent vs continuous ADT: Still controversial?
12.50- 13.05	Local treatment of oligometastatic disease: Lymphadenectomy
13.05- 13.20	Bone metastases
13.20 - 13.35	When should we start treatment in CRPC patients?
13.35 - 13.45	Discussion
13.45	Meeting close